- Home
- CDXS vs ZNTL Comparison
CDXS vs ZNTL Comparison
Compare CDXS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDXS | ZNTL |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 289.0M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CDXS | ZNTL |
|---|---|---|
| Price | $2.47 | $4.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 939.7K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.82 | 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $138,590,000.00 | N/A |
| Revenue This Year | $7.73 | N/A |
| Revenue Next Year | $14.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | N/A |
| 52 Week Low | $0.96 | $1.15 |
| 52 Week High | $3.87 | $6.95 |
Technical Indicators
Market Signals| Indicator | CDXS | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 59.31 |
| Support Level | $2.41 | $3.53 |
| Resistance Level | $2.69 | $6.95 |
| Average True Range (ATR) | 0.15 | 0.38 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 63.44 | 60.37 |
Price Performance
Historical ComparisonAbout CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.